Pfizer: The Covid Reset Makes Sense (NYSE:PFE)
Assuming an upward rerating, PFE could hit our price target of $55.79, suggesting 27.40% upside potential from current levels. Click here to read our analysis.
Source: seekingalpha.com
Page 11 - Array Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Array Biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Array Biopharma Today - Breaking & Trending Today
Pfizer to ease development of early-stage rare disease assets - Barron's (NYSE:PFE)
Pfizer (PFE) on Thursday told employees that it is lifting early-stage research into rare diseases and externalize this, according to Barron's.
Source: seekingalpha.com
Deciphera: Encouraging Sales Growth For Qinlock But Risk/Reward Unattractive (NASDAQ:DCPH)
Investors should steer clear of Deciphera shares. Read why the risk/reward profile does not look attractive at this time.
Source: seekingalpha.com
Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds
Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.
Source: medcitynews.com